Entera Bio

Entera Bio

Yahoo Finance • 3 days ago

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

EB612, a first-in-class long-acting PTH(1-34) oral peptide  for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026 EB618, a first-in-class d... Full story

Yahoo Finance • 4 days ago

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

Entera Bio Ltd. The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 Single tablet EB613 achieved a comparable... Full story

Yahoo Finance • last month

Entera Bio GAAP EPS of -$0.07 beats by $0.02

* Entera Bio press release [https://seekingalpha.com/pr/20508125-entera-announces-first-quarter-2026-financial-results-and-updates-across-its-oral-peptide] (ENTX [https://seekingalpha.com/symbol/ENTX]): Q1 GAAP EPS of -$0.07 beats by $0.... Full story

Yahoo Finance • last month

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted to ENDO2026 and ASBMR EB612, the first... Full story

Yahoo Finance • 3 months ago

Entera Bio prices $10M direct investment, sees up to $24.5M in total proceeds

* Entera Bio (ENTX [https://seekingalpha.com/symbol/ENTX]) said [https://seekingalpha.com/pr/20460875-entera-bio-announces-pricing-of-10_0-million-direct-investment-by-bvf-partners-with-potential] on Thursday it had entered into a securi... Full story

Yahoo Finance • 3 months ago

Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates

EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with comments expected in early Q2 2026 EB612, th... Full story

Yahoo Finance • 4 months ago

Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis

Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 as Phase 3 candidate, following succe... Full story

Yahoo Finance • 4 months ago

Opko Health (OPK) Expands Entera Partnership for Drug Co-Development

Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $3 to invest in. On February 4, Opko Health Inc. (NASDAQ:OPK) announced it expanded its partnership with Entera Bio Ltd., a company developing oral peptide and protein replaceme... Full story

Yahoo Finance • 7 months ago

Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference

JERUSALEM, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies, today announced that the Company’s Chief Executive Of... Full story

Yahoo Finance • 7 months ago

Entera Bio GAAP EPS of $0.07

* Entera Bio press release [https://seekingalpha.com/pr/20308640-entera-bio-announces-third-quarter-2025-financial-results-and-business-updates] (ENTX [https://seekingalpha.com/symbol/ENTX]): Q3 GAAP EPS of $0.07. * Research and develo... Full story

Yahoo Finance • 7 months ago

Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates

FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Impact on Trabecular and Cortical Bone In... Full story

Yahoo Finance • 8 months ago

Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting

JERUSALEM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today announced that it will present new clinical data from its Phase 2 trial of... Full story

Yahoo Finance • 10 months ago

Entera Bio GAAP EPS of -$0.06 beats by $0.10

* Entera Bio press release [https://seekingalpha.com/pr/20195250-entera-bio-announces-second-quarter-2025-financial-results-and-business-updates] (NASDAQ:ENTX [https://seekingalpha.com/symbol/ENTX]): Q2 GAAP EPS of -$0.06 beats by $0.10.... Full story

Yahoo Finance • 10 months ago

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatment Significant regulatory and pipeline advanceme... Full story

Yahoo Finance • 11 months ago

OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results

OPKO Health, Inc. Conference call begins at 4:30 p.m. Eastern time today MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 3... Full story

Yahoo Finance • 11 months ago

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis

JERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response to a Type A meeting request, the U.S.... Full story

Yahoo Finance • 11 months ago

OPKO Health’s (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)

OPKO Health, Inc. (NASDAQ:OPK) is one of the Best American Penny Stocks to Buy According to Analysts. On July 8, OPKO Health, Inc. (NASDAQ:OPK) in collaboration with Entera Bio Ltd. (NASDAQ: ENTX) announced the selection of their Oral GLP-... Full story

Yahoo Finance • 11 months ago

InvestingPro's Fair Value model correctly predicted Entera Bio's downward shift

When making investment decisions, understanding a stock’s true value is crucial for achieving optimal returns. This was demonstrated clearly in Investing.com’s Fair Value analysis of Entera Bio Ltd . (NASDAQ:ENTX), which accurately identi... Full story

Yahoo Finance • last year

Entera Bio files $100M mixed securities shelf

* Entera Bio (NASDAQ:ENTX [https://seekingalpha.com/symbol/ENTX]) filed $100M mixed securities shelf * Filing [https://seekingalpha.com/filing/10047026] MORE ON ENTERA BIO * Entera Bio GAAP EPS of -$0.06 beats by $0.01 [https://see... Full story

Yahoo Finance • last year

Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates

JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business achievements for the year en... Full story